Drug Combination Details
| General Information of the Combination (ID: C27955) | |||||
|---|---|---|---|---|---|
| Name | Ursolic acid NP Info | + | Oxaliplatin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Colorectal cancer
[ICD-11: 2B91]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | ERK2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | IKKA | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SW480 | CVCL_0546 | Colon adenocarcinoma | Homo sapiens | ||
| SW620 | CVCL_0547 | Colon adenocarcinoma | Homo sapiens | |||
| LoVo | CVCL_0399 | Colon adenocarcinoma | Homo sapiens | |||
| RKO | CVCL_0504 | Colon carcinoma | Homo sapiens | |||
| In-vivo Model | SW620 cells (1*107) were injected subcutaneously into the right flank area of 6-8-week-old female nude mice. | |||||
| Experimental
Result(s) |
Ursolic acid inhibited proliferation and induced apoptosis of all four cells, enhanced the cytotoxicity of oxaliplatin, and restored liver function and body weight of the mice treated with oxaliplatin. | |||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [3] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | ABCB1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | ABCG2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MSH3 | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Up-regulation | ROS generation | ||||
| In-vitro Model | HCT 8 | CVCL_2478 | Colon adenocarcinoma | Homo sapiens | ||
| SW480 | CVCL_0546 | Colon adenocarcinoma | Homo sapiens | |||
| In-vivo Model | 1*105 HCT8 or SW480 cells were injected subcutaneously into the right flank area of 6-8-week-old female nude mice. | |||||
| Experimental
Result(s) |
Ursolic acid enhances the therapeutic effects of oxaliplatin in colorectal cancer by inhibition of drug resistance. | |||||
| Experiment 2 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Activity | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Activity | CASP8 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Activity | CASP9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | XIAP | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | RKO | CVCL_0504 | Colon carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Ursolic acid potentiated oxaliplatin to induce apoptosis in colorectal cancer RKO cells and increased the activities of caspase-3, caspase-8, and caspase-9. | |||||
